CombiMatrix Appoints Lâle White to Board of Directors

IRVINE, Calif., March 16, 2015 (GLOBE NEWSWIRE) — CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for pre- and postnatal developmental disorders, today announced that veteran healthcare executive Lâle White has been appointed to the CombiMatrix Board of Directors, effective March 12, 2015. White fills a current vacancy on the CombiMatrix Board, which is now made up of six directors following White’s appointment.

White, who is CEO of XiFin, Inc., is a nationally recognized expert in the field of healthcare financial management and regulatory compliance, with over 25 years of experience in information systems development and medical billing. She lectures extensively on these topics and has consulted for major laboratories and laboratory associations throughout the U.S. White worked with HCFA and the U.S. Office of the Inspector General to develop the first OIG Model Compliance Program. She is a member of the Board of Directors of bioTheranostics, part of the worldwide bioMerieux group, and is a longstanding member of the California Clinical Lab Association, where for the last eight years she has chaired the state and federal contractor committees that work with the Medicare Administrative Contractors and the Department of Health and Human Services.

White was previously vice president – finance of Laboratory Corporation of America, one of the largest clinical reference laboratories in the U.S., and its predecessor National Health Laboratories, where she led the software development of several accounts receivable, inventory, cost accounting and financial management systems for the laboratory industry. White has a BA in finance and an MBA from Florida International University.

“We are very pleased to welcome Lâle to our Board at this exciting time for CombiMatrix,” said Mark McDonough, President and Chief Executive Officer of CombiMatrix. “The prenatal molecular diagnostic market is growing rapidly, and we are very focused on continuing to grow our business through increased utilization and improved reimbursement. We are committed to our strategy to have third-party payors reimburse us for the medically necessary tests we run that daily provide physicians, patients, and families with critical and meaningful diagnostic information. We believe that Lâle’s wealth of healthcare experience coupled with her vast expertise in medical billing and reimbursement will be especially valuable to us as we continue to execute on our commercial plan. We look forward to working closely with Lâle during this important stage of our company’s growth.”

About CombiMatrix Corporation

CombiMatrix Corporation provides valuable molecular diagnostic solutions and comprehensive clinical support to foster the highest quality in patient care. CombiMatrix specializes in pre-implantation genetic screening (PGS), prenatal diagnosis, miscarriage analysis, and pediatric genetics, offering DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies. CombiMatrix performs genetic testing utilizing a variety of advanced cytogenomic techniques, including chromosomal microarray, standardized and customized fluorescence in situ hybridization (“FISH”) and high-resolution karyotyping. CombiMatrix is dedicated to providing high-level clinical support for healthcare professionals in order to help them incorporate the results of complex genetic testing into patient-centered medical decision making. Additional information about CombiMatrix is available at www.combimatrix.com or by calling 1-800-710-0624.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations, speak only as of the date hereof and are subject to change. All statements, other than statements of historical fact included in this press release, are forward-looking statements. Forward-looking statements can often be identified by words such as “anticipates,” “expects,” “intends,” “plans,” “goal,” “predicts,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” “would,” “could,” “potential,” “continue,” “ongoing,” “objective,” similar expressions, and variations or negatives of these words. These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause our actual results to differ materially and adversely from those expressed in any forward-looking statement. The risks and uncertainties referred to above include, but are not limited to: the risk that reimbursement trends do not improve; market acceptance of CMA as a preferred method over karyotyping; the rate of transition to CMA from karyotyping; our ability to successfully expand the base of our customers and strategic partners, add to the menu of our diagnostic tests in both of our primary markets, develop and introduce new tests and related reports, optimize the reimbursements received for our testing services, and increase operating margins by improving overall productivity and expanding sales volumes; our ability to successfully accelerate sales, allow access to samples earlier in the testing continuum, steadily increase the size of our customer rosters in pre- and postnatal genetic medicine; our ability to attract and retain a qualified sales force; rapid technological change in our markets; changes in demand for our future products; legislative, regulatory and competitive developments; general economic conditions; and various other factors. Further information on potential factors that could affect our financial results is included in our Annual Report on Form 10-K, Quarterly Reports of Form 10-Q, and in other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update publicly any forward-looking statements for any reason, except as required by law.

CONTACT: Company Contact:
Mark McDonough
President & CEO, CombiMatrix Corporation
Tel (949) 753-0624

Investor Contact:
Robert Flamm, Ph.D.
Russo Partners, LLC
(212) 845-4226
robert.flamm@russopartnersllc.com

Media Contact:
David Schull or Lena Evans
Russo Partners LLC
(212) 845-4271 or (212) 845-4262
david.schull@russopartnersllc.com
lena.evans@russopartnersllc.com

Source: CombiMatrix Corporation
News Provided by Acquire Media

About XiFin

XiFin, Inc. is an innovative software and services company dedicated to optimizing the economics of healthcare. XiFin’s mission is to deliver value to our customers through exceptional technology and services that provide the necessary metrics and knowledge to enable healthcare providers to drive out costs while maximizing value from their financial operations. We believe this vision is the key to unlocking a world where healthcare operates with efficiency and makes informed, optimized decisions, where information helps build healthy organizations and deliver the best care and patient outcomes possible. Follow XiFin on Twitter at www.twitter.com/#!/XiFin.